A wide range of new PBS listings for arthritis drugs have been given the green light, including golimumab for non-radiographic axial spondyloarthritis (nr-axSpA) and two new biosimilars for adalimumab. Other positive recommendations for PBS listing from the Pharmaceutical Benefits Advisory Committee include ixekizumab for severe psoriatic arthritis and new forms of adalimumab, tocilizumab and subcutaneous ...
PBS listings for nr-axSpA biologic and adalimumab biosimilars
By Michael Woodhead
21 Aug 2018